Sign inJoin waitlistJoin the waitlist

Jo Chien

Medical Oncology · Ucsf Medical Group Business Services

Credentials: · ·

History

Hematology and Medical Oncology
University of California (San Francisco) School of Medicine
2006–2009
Internal Medicine
Massachusetts General Hospital
2003–2006
Harvard Medical School
1999–2003
Harvard University
1995–1999

Research

Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively…
JAMA Oncology · 2020 · 610 citations
Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial
Journal of Clinical Oncology · 2020 · 452 citations
Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer
New England Journal of Medicine · 2016 · 452 citations

Hope Rugo
58 papers
Laura Esserman
50 papers
Michelle Melisko
41 papers
Angela DeMichele
26 papers
Douglas Yee
25 papers
Claudine Isaacs
24 papers
William Symmans
23 papers
Rita Nanda
22 papers
Judy Boughey
21 papers · 4 as a resident
Anne Wallace
19 papers
Kathy Albain
19 papers
Anthony Elias
16 papers

Clinical trials

T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer
Principal investigator · Completed · Phase 1
University of California, San Francisco
2020–2023
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Site PI · Recruiting · Phase 3
Eli Lilly and Company
2025–2033
A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer
Site PI · Recruiting · Phase 1
Stemline Therapeutics, Inc.
2024–2029
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
Site PI · Recruiting · Phase 2
QuantumLeap Healthcare Collaborative
2010–2031